Navigation Links
Boston Scientific Completes Clinical Trial Enrollment for Third-Generation Drug-Eluting Stent
Date:10/8/2008

investigational device and is limited by Federal law to investigational use only and is not available for sale. Boston Scientific is currently seeking CE Mark approval in European markets, which is anticipated in 2009.

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: http://www.bostonscientific.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward- looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding clinical trials, regulatory approvals, competitive offerings, product performance and our market position. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward- looking statements.

Factors that may cause such differences include, among other things: future economic, competitive, rei
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Wound Management Technologies, Inc. Announces Conference Plans in Boston and Additional Clinical Research on CellerateRx(R)
2. NIH Funds New Wellstone Research Center for Muscular Dystrophy at Boston Biomedical Research Institute
3. Boston Scientific Announces Schedule for European Society of Cardiology Congress 2008
4. Boston University and The Center for Human Genetics, Inc. Announce Change in Testing Services
5. Headache Specialists Convene in Boston For 50th Annual American Headache Society Meeting
6. Leading Immunologists Convene in Boston
7. Seven Presentations by Two Independent Research Groups Highlight Advantages of Pressure Cycling Technology (PCT) at Scientific Symposia in Philadelphia, Boston, and New York City
8. Multi-Center Patient Registry Supports Safety and Clinical Utility of Boston Scientifics SpyGlass(R) Direct Visualization System
9. SPIRIT III Results Reaffirm Strong Performance of Boston Scientific PROMUS(TM) and TAXUS(R) Express(R) Stents
10. Cequent Pharmaceuticals Johannes Fruehauf, MD, Ph.D., to be Featured Speaker at RNAi World Congress in Boston - May 2, 2008
11. Spirit II Results Support Strength of Boston Scientifics Two Drug-Eluting Stent Platforms
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... , Aug. 19, 2014  Boehringer Ingelheim today ... (FDA) accepted for review the New Drug Application ... and olodaterol delivered via the Respimat ® ... maintenance treatment of airflow obstruction in patients with ... and/or emphysema. Tiotropium + olodaterol FDC will not ...
(Date:8/19/2014)... -- According to Kalorama Information, electronic medical records (EMR) ... in healthcare a reality, and this a factor that ... Recovery and Reinvestment Act, the U.S. government dedicated $20.6 ... will start applying soon for use of paper records.  ... of the EMR industry, EMR 2014: The Market ...
(Date:8/19/2014)... Calif. , Aug. 19, 2014  Cardiva Medical, ... two tranches of a $16.5 million Series 3 private ... with GE Capital. The Company will use the proceeds ... facility to expand commercial efforts for its VASCADE® Vascular ... . Investing in Series 3 private ...
Breaking Medicine Technology:Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 2Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 3Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 4Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 5Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 6Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 7Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 8Kalorama: EMR Paves the Way for Big Data 2Kalorama: EMR Paves the Way for Big Data 3Cardiva Medical, Inc. Announces Completion of the first two tranches of Series 3 Private Equity Financing and the Closing of a Senior Secured Debt Facility with GE Capital 2
(Date:8/20/2014)... Universities of Manchester and Auckland suggest that both major forms ... , The findings, published today in the FASEB Journal ... diabetes and type-2 diabetes are both caused by the formation ... , The results, based on 20 years, work in New ... slowed down and potentially reversed by medicines that stop amylin ...
(Date:8/20/2014)... extracted acellular allogeneic nerve, from which Schwann ... been removed, reduced postoperative immune rejection. Simultaneously, ... substrates and base materials, such as the ... provide a good scaffold in the process ... nerve, similar to autologous nerve transplantation, can ...
(Date:8/20/2014)... The Workgroup for Electronic Data ... the use of health IT to create efficiencies ... for its annual fall conference, WEDI-Con 2014: The ... will take place at the HYATT Regency in ... diverse cross-section of payers, providers, government regulators, industry ...
(Date:8/20/2014)... August 20, 2014 If old age is ... cure for it. With extensive research on HGH and stem ... claims to have perfected the art of rubbing off decades ... new younger look with their revolutionary anti-aging hormone therapy and ... 21st century fountain of youth, the MD of MetroMD, Dr ...
(Date:8/20/2014)... The National Association of Hispanic Nurses ... Education Partnership Award (SEPA) grant from the National ... with the Hispanic Communications Network (HCN) entitled Hispanic ... NIH R25 program has been established to address ... health professionals by recruiting and interviewing bilingual role ...
Breaking Medicine News(10 mins):Health News:Scientists show type-1 and type-2 diabetes are caused by same underlying mechanism 2Health News:WEDI Releases Full Conference Agenda for Its Annual Fall Conference – WEDI-Con 2014 2Health News:WEDI Releases Full Conference Agenda for Its Annual Fall Conference – WEDI-Con 2014 3Health News:MetroMD Offers Revolutionary Anti-aging Hormone Therapy in Hollywood Area 2Health News:National Association of Hispanic Nurses (NAHN) Receives Five-Year Federal Grant from the National Institutes of Health (NIH) 2Health News:National Association of Hispanic Nurses (NAHN) Receives Five-Year Federal Grant from the National Institutes of Health (NIH) 3
... 18 Codexis, Inc. today announced that Joseph Sarret, ... Corporate Development from his previous position as Vice President, ... Shaw, Ph.D., President and CEO. Dr. Sarret was ... joined Codexis in 2005 as Corporate Counsel and Director, ...
... Inc. (Nasdaq: MDVN ) today announced ... U.S. Food and Drug Administration (FDA) to begin ... novel androgen receptor antagonist, in patients with metastatic ... chemotherapy. The placebo-controlled, double-blind, multinational trial will ...
... smaller and more contained, study finds , , WEDNESDAY, March 18 ... reduce the risk of death by as much as half, ... information on 1,044 women who were seen at a medical ... had developed a second breast cancer -- 455 with cancer ...
... PHR Taps into Latino Market Underserved by ... Information Systems, Inc. (OTC Bulletin Board: FVRL), ... Inc. (collectively, "MMR") provides consumer-controlled Personal Health ... safe deposit box storage solutions ( www.myesafedepositbox.com ...
... 18 Kensey Nash Corporation (Nasdaq: KNSY ) ... stock repurchase. The new program allows the Company to ... and outstanding shares of Common Stock and has no scheduled ... its available cash. "Given our strong cash position and the ...
... they learned from elders who have been through economic ... simply being thankful can calm economic anxiety; other key ... optimism; what to avoid?: elders say don,t listen to ... released in conjunction with national conference Aging in America ...
Cached Medicine News:Health News:Codexis Names Sarret SVP, Corporate Development 2Health News:Medivation Receives FDA Permission to Initiate Phase 3 Trial of MDV3100 in Castration-Resistant Prostate Cancer 2Health News:Medivation Receives FDA Permission to Initiate Phase 3 Trial of MDV3100 in Castration-Resistant Prostate Cancer 3Health News:Medivation Receives FDA Permission to Initiate Phase 3 Trial of MDV3100 in Castration-Resistant Prostate Cancer 4Health News:When Breast Cancer Recurs, Finding Pre-Symptoms Is Key 2Health News:MMR Information Systems Offers First Bilingual Personal Health Record Through The Latino Coalition 2Health News:MMR Information Systems Offers First Bilingual Personal Health Record Through The Latino Coalition 3Health News:MMR Information Systems Offers First Bilingual Personal Health Record Through The Latino Coalition 4Health News:Kensey Nash Announces 600,000 Share Stock Repurchase Program 2Health News:Kensey Nash Announces 600,000 Share Stock Repurchase Program 3Health News:New Survey: Top Lesson from Seniors About Economic Worries? Gratitude Trumps Fear 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: